The role of vascular endothelial growth factor genetic variability in cancer

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Angiogenesis is a hallmark of tumor pathogenesis. Vascular endothelial growth factor (VEGF) is a critical regulator of angiogenesis and its inhibition has become a successful approach to antitumor therapy across tumor types. The VEGF gene is highly polymorphic with multiple common single nucleotide polymorphisms (SNPs) in the promoter, 5′ untranslated region and 3′ untranslated region. There is evidence that these SNPs in the regulatory regions can affect VEGF expression. In vitro and in vivo data showthat genetic variability affects the activity and expression of VEGF. Case-control and cohort studies suggest that genetic variability may affect risk and outcome of a variety of disease states that are tightly regulated by angiogenesis. Recently, genetic variability in VEGF has been studied as a potential predictive biomarker for bevacizumab. The VEGF-1154 AA and -2578 AA genotypes predicted an improved median overall survival, whereas the VEGF-634 CC and -1498 TT genotypes predicted protection from grade 3-4 hypertension in the pivotal trial, E2100. If validated, these finding could help direct which subgroup of patients should receive bevacizumab.

Original languageEnglish
Pages (from-to)5297-5302
Number of pages6
JournalClinical Cancer Research
Volume15
Issue number17
DOIs
StatePublished - Sep 1 2009

Fingerprint

Vascular Endothelial Growth Factor A
Neoplasms
Single Nucleotide Polymorphism
Genotype
Nucleic Acid Regulatory Sequences
5' Untranslated Regions
3' Untranslated Regions
Case-Control Studies
Cohort Studies
Biomarkers
Hypertension
Survival
Genes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

The role of vascular endothelial growth factor genetic variability in cancer. / Schneider, Bryan; Radovich, Milan; Miller, Kathy.

In: Clinical Cancer Research, Vol. 15, No. 17, 01.09.2009, p. 5297-5302.

Research output: Contribution to journalArticle

@article{d9f9a966456644909c8202197f9e1809,
title = "The role of vascular endothelial growth factor genetic variability in cancer",
abstract = "Angiogenesis is a hallmark of tumor pathogenesis. Vascular endothelial growth factor (VEGF) is a critical regulator of angiogenesis and its inhibition has become a successful approach to antitumor therapy across tumor types. The VEGF gene is highly polymorphic with multiple common single nucleotide polymorphisms (SNPs) in the promoter, 5′ untranslated region and 3′ untranslated region. There is evidence that these SNPs in the regulatory regions can affect VEGF expression. In vitro and in vivo data showthat genetic variability affects the activity and expression of VEGF. Case-control and cohort studies suggest that genetic variability may affect risk and outcome of a variety of disease states that are tightly regulated by angiogenesis. Recently, genetic variability in VEGF has been studied as a potential predictive biomarker for bevacizumab. The VEGF-1154 AA and -2578 AA genotypes predicted an improved median overall survival, whereas the VEGF-634 CC and -1498 TT genotypes predicted protection from grade 3-4 hypertension in the pivotal trial, E2100. If validated, these finding could help direct which subgroup of patients should receive bevacizumab.",
author = "Bryan Schneider and Milan Radovich and Kathy Miller",
year = "2009",
month = "9",
day = "1",
doi = "10.1158/1078-0432.CCR-08-2576",
language = "English",
volume = "15",
pages = "5297--5302",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "17",

}

TY - JOUR

T1 - The role of vascular endothelial growth factor genetic variability in cancer

AU - Schneider, Bryan

AU - Radovich, Milan

AU - Miller, Kathy

PY - 2009/9/1

Y1 - 2009/9/1

N2 - Angiogenesis is a hallmark of tumor pathogenesis. Vascular endothelial growth factor (VEGF) is a critical regulator of angiogenesis and its inhibition has become a successful approach to antitumor therapy across tumor types. The VEGF gene is highly polymorphic with multiple common single nucleotide polymorphisms (SNPs) in the promoter, 5′ untranslated region and 3′ untranslated region. There is evidence that these SNPs in the regulatory regions can affect VEGF expression. In vitro and in vivo data showthat genetic variability affects the activity and expression of VEGF. Case-control and cohort studies suggest that genetic variability may affect risk and outcome of a variety of disease states that are tightly regulated by angiogenesis. Recently, genetic variability in VEGF has been studied as a potential predictive biomarker for bevacizumab. The VEGF-1154 AA and -2578 AA genotypes predicted an improved median overall survival, whereas the VEGF-634 CC and -1498 TT genotypes predicted protection from grade 3-4 hypertension in the pivotal trial, E2100. If validated, these finding could help direct which subgroup of patients should receive bevacizumab.

AB - Angiogenesis is a hallmark of tumor pathogenesis. Vascular endothelial growth factor (VEGF) is a critical regulator of angiogenesis and its inhibition has become a successful approach to antitumor therapy across tumor types. The VEGF gene is highly polymorphic with multiple common single nucleotide polymorphisms (SNPs) in the promoter, 5′ untranslated region and 3′ untranslated region. There is evidence that these SNPs in the regulatory regions can affect VEGF expression. In vitro and in vivo data showthat genetic variability affects the activity and expression of VEGF. Case-control and cohort studies suggest that genetic variability may affect risk and outcome of a variety of disease states that are tightly regulated by angiogenesis. Recently, genetic variability in VEGF has been studied as a potential predictive biomarker for bevacizumab. The VEGF-1154 AA and -2578 AA genotypes predicted an improved median overall survival, whereas the VEGF-634 CC and -1498 TT genotypes predicted protection from grade 3-4 hypertension in the pivotal trial, E2100. If validated, these finding could help direct which subgroup of patients should receive bevacizumab.

UR - http://www.scopus.com/inward/record.url?scp=69949107753&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69949107753&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-08-2576

DO - 10.1158/1078-0432.CCR-08-2576

M3 - Article

C2 - 19706811

AN - SCOPUS:69949107753

VL - 15

SP - 5297

EP - 5302

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 17

ER -